Shi D M, Han H Y
12th Ward, Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease,Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease, Capital Medical University,Beijing 100029, China.
Zhonghua Wai Ke Za Zhi. 2020 May 1;58(5):341-344. doi: 10.3760/cma.j.cn112139-20200125-00047.
Hybrid coronary revascularization (HCR) combines the respective strengths of coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) for selected patients with multivessel coronary artery disease. HCR includes the minimally invasive direct coronary artery bypass of a left internal thoracic artery graft to the left anterior descending artery (LAD) with stenting of non-LAD lesions with PCI, in onestop or staged hybrid procedures.HCR can prove superiority to conventional CABG in clinical complications. Many available data suggests that HCR is feasible and safe in skilled hands. Further large-scale randomized controlled trials are in great need. HCR may become another more commonly used interventional strategy for certain patients with multivessel coronary artery disease.
杂交冠状动脉血运重建术（HCR）结合了冠状动脉旁路移植术（CABG）和经皮冠状动脉介入治疗（PCI）的各自优势，用于特定的多支冠状动脉疾病患者。HCR包括通过微创直接冠状动脉旁路移植术将左乳内动脉移植至左前降支（LAD），同时通过PCI对非LAD病变进行支架置入，可采用一站式或分期杂交手术。HCR在临床并发症方面可能优于传统CABG。许多现有数据表明，在技术熟练的医生手中，HCR是可行且安全的。迫切需要进一步的大规模随机对照试验。对于某些多支冠状动脉疾病患者，HCR可能会成为另一种更常用的介入策略。
